Vanguard Capital Management
TVRD

Vanguard Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Vanguard Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$654K Sell
344,382
-326
-0.1% -$1.02K ﹤0.01% 3671
2026
Q1 		$1.1M Buy
+344,708
New +$1.35M ﹤0.01% 3525

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management's TVRD Position: Q2 2026 in Review

Vanguard Capital Management reduced its Tvardi Therapeutics (TVRD) stake by 0.09% in Q2 2026, selling an estimated $1.02K and leaving 344,382 shares worth $654K. The position accounts for ﹤0.01% of the portfolio, ranked #3671.

Vanguard Capital Management first reported a position in TVRD in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.1M in Q1 2026. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Vanguard Capital Management held 344,382 shares of Tvardi Therapeutics worth $654K as of Q2 2026.
  • Vanguard Capital Management sold 326 Tvardi Therapeutics shares in Q2 2026, an estimated $1.02K.
  • Tvardi Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3671 holding.
  • Vanguard Capital Management first reported a position in Tvardi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Tvardi Therapeutics position peaked at $1.1M in Q1 2026.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.